Daniel Faga’s holdings have seen significant fluctuations recently. When he began his role as CEO, the value of his stock holdings in AnaptysBio was around $25.5 million. However, by March 2023, this figure dipped to approximately $17.7 million, indicating a...

Daniel Faga’s holdings have seen significant fluctuations recently. When he began his role as CEO, the value of his stock holdings in AnaptysBio was around $25.5 million. However, by March 2023, this figure dipped to approximately $17.7 million, indicating a volatile market. Over the months, his investments varied, sometimes reaching as high as $24.11 million in October 2022 before stabilizing at around $16.16 million in October 2023. This reflects the day-to-day ups and downs of being involved in a biotech firm where the market can react sharply to clinical trial results and regulatory updates.